4D Molecular Therapeutics, Inc.
As of Oct 22, 2026, 4D Molecular Therapeutics is in Stage 2, the uptrend phase, now in week 30 (since Mar 23, 2026). It closed at $11.85, 29.3% below its 52-week high and above its 200-day average, which is rising.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is FDMT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
FDMT among Biotechnology170th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …170 | FDMT | Stage 2 · wk 30 | 59 | −21.0% |
4D Molecular Therapeutics: quick answers
What stage is 4D Molecular Therapeutics in?
As of Oct 22, 2026, 4D Molecular Therapeutics (FDMT) is in Stage 2, the uptrend phase. It entered Stage 2 on Mar 23, 2026 and is in week 30. What the four stages mean
Is 4D Molecular Therapeutics in an uptrend?
Yes. 4D Molecular Therapeutics is in a Stage 2 uptrend. It trades 10.2% above its 200-day average, which is rising.
How far is 4D Molecular Therapeutics from its 52-week high?
4D Molecular Therapeutics closed at $11.85 on Oct 22, 2026, 29.3% below its 52-week high of $16.76. Its 52-week low is $7.19.
How has 4D Molecular Therapeutics performed over the past year?
As of Oct 22, 2026, 4D Molecular Therapeutics is up 5.4% over the past year and up 61.9% so far in 2026.
Which sector and industry is 4D Molecular Therapeutics in?
4D Molecular Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.